1. Home
  2. PUMP vs KALV Comparison

PUMP vs KALV Comparison

Compare PUMP & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProPetro Holding Corp.

PUMP

ProPetro Holding Corp.

HOLD

Current Price

$16.94

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.76

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUMP
KALV
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
PUMP
KALV
Price
$16.94
$26.76
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$14.14
$32.60
AVG Volume (30 Days)
4.6M
4.4M
Earning Date
04-30-2026
07-09-2026
Dividend Yield
N/A
N/A
EPS Growth
100.76
N/A
EPS
N/A
N/A
Revenue
$1,269,158,000.00
$50,000,000.00
Revenue This Year
N/A
$185.42
Revenue Next Year
$15.61
$59.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
495.66
52 Week Low
$4.51
$9.83
52 Week High
$18.50
$26.85

Technical Indicators

Market Signals
Indicator
PUMP
KALV
Relative Strength Index (RSI) 59.37 75.12
Support Level $14.90 $14.66
Resistance Level N/A N/A
Average True Range (ATR) 0.98 0.25
MACD -0.09 0.08
Stochastic Oscillator 56.67 98.93

Price Performance

Historical Comparison
PUMP
KALV

About PUMP ProPetro Holding Corp.

ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: